Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | QRFPR | Q96P65 | 6/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12010845 | 0.82 | DRD2 (0.47) | DRD2DRD1HRH3QRFPRKCNH2 | |
| SCHEMBL14016691 | 0.81 | QRFPR (0.40) | HRH3QRFPRKCNH2CYP2D6KCNE1 | |
| SCHEMBL3282829 | 0.76 | HRH3 (0.51) | HRH3CYP2D6PARP1 | |
| SCHEMBL3279061 | 0.76 | HRH3 (0.41) | HRH3KCNH2PARP1ALDH1A1 | |
| SCHEMBL7645219 | 0.75 | DRD2 (0.55) | DRD2DRD1HRH3KCNH2PNMT | |
| SCHEMBL13171826 | 0.75 | HRH3 (0.50) | DRD2DRD1HRH3PNMTALDH1A1 | |
| SCHEMBL20889998 | 0.75 | HRH3 (0.50) | DRD2DRD1HRH3PNMTALDH1A1 | |
| SCHEMBL3284914 | 0.74 | ESR1 (0.51) | QRFPRKCNH2CYP2D6KCNE1SCN5A | |
| SCHEMBL11474315 | 0.74 | DRD1 (0.82) | DRD2DRD1HRH3PNMTALDH1A1 | |
| SCHEMBL1905994 | 0.74 | DRD2 (0.54) | DRD2DRD1HRH3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439237-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | DRD2 608/4885DRD1 658/4885HRH3 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.